Recently, the 3-year safety outcomes of the SURMOUNT-1 trial with tirzepatide (dual GIP/GLP-1 RA) were reported, confirming its efficacy in reducing weight and delaying progression to T2D in persons with both obesity and prediabetes [58]. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.